(Moderna Inc.) Biotech company Moderna Inc. has inked a deal with the Canadian government to build a state-of-the-art messenger RNA vaccine manufacturing facility in the country. The manufacturing facility is…
(Swissmedic) Moderna stock closed up more than 17% on Monday following news that its Covid-19 vaccine has been approved by Swissmedic for use in teens between 12 to 17 years.…
(Financial Times) Vaccine makers Pfizer Inc. and Moderna Inc. have raised their Covid-19 vaccine prices days after signing new supply contracts in the European Union. Pfizer’s short will now sell…
(Bloomberg) Vaccine maker Moderna Inc. jumped about 11% on Friday to reach a new record high of $288.88 after reports of inclusion on S&P 500 surfaced. S&P Dow Jones announced,…
Moderna is funding plans to raise the global supply of COVID-19 vaccine to 3 billion doses by 2022, according to the company’s press release. The company has also raised its…
Moderna Inc. has raised its manufacturing plans for the next two years, according to the company’s press release. The biotechnology company targets to increase capacity to 1.4 billion doses of…
Moderna studies showed its Covid vaccine retains neutralizing activity against emerging strains of SARS-CoV-2, according to the company’s press release. The vaccine neutralizes all key emerging variants, including B.1.1.7 and…
Roche has announced a partnership with Moderna to use its Elecsys Anti-SARS-CoV-2 S antibody test in Moderna's mRNA-1273 vaccine trials, according to Roche’s press release. Roche's anti-SARS-CoV-2 antibody test detects…
A preliminary large late-stage clinical trial has shown Moderna’s COVID-19 vaccine candidate is 94.5% effective in preventing COVID-19 and has no significant safety concerns, according to the company’s press release.…
Traders are worried that complacency over the coronavirus vaccine could affect markets, according to CNBC. Five vaccines, from Moderna, AstraZeneca, Pfizer, Johnson & Johnson, and Novavax are in phase 3…